Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
PASTA and pizza chain Prezzo is to add up to 30 new restaurants to its estate this year after serving up another healthy rise in profits yesterday. PASTA and pizza chain Prezzo is to add up to 30 new restaurants to its estate this year after serving up another healthy rise in profits yesterday. Sorry, you must sign in before you can print full articles. The group, which trades as Prezzo, Chimichanga Tex-Mex and Cleaver, opened 28 new sites during the financial year to December 29 as it expanded to 237 outlets and lifted adjusted profits by 11% to £20.4 million. The opening programme provided it with its first presence in major cities such as Belfast and Leeds, as well as additional sites in Bath, Oxford and Glasgow. It has opened one new restaurant in Ripon this year, and is on site in a further six locations as it looks to add another 25 to 30 new outlets in 2014. Chairman Michael Carlton said the company's record of growth during the economic downturn meant there was "every reason to be positive" about future performance now that the UK's prospects were improving. He added: "We have enjoyed an encouraging start to the year, and with a strong site pipeline in place, the board is confident of further success in 2014." The company said it saw positive early signs for Cleaver, which offers chicken, ribs and burger from an open-grill kitchen, following the launch of sites at Cobham, Leatherhead, Wokingham and Oxford since last summer. Initially called Jonathans, the group opened in November 2000 and floated on the Alternative Investment Market in March 2002. The chain is controlled by the Kaye restaurant dynasty, with various family members together holding more than half of its shares. Chief executive Jonathan Kaye has about 8.5%, while his uncle, Philip - the co-founder of Garfunkel's and Deep Pan Pizza - has 46% of the stock.
A better day so far!
Enjoy a free Antipasto for One when you pay your bill by Paypal using the Prezzo App.*
Great Results, Taudelta. I am delighted to read another set of strong results for the 52 weeks ending 29 December 2013. Really pleasing with a healthy EPS too. A nice upgrade from Panmure which is more generous than Numis's. I know the last two days saw Investors offloading stocks with a few here too. I suspect they will be back. Well done Prezzo!
Don't think there are any problems. It's just a shakey Market over recent days. I did note one fund manager commenting that he thought ETO is now fairly priced, so maybe some profit taking from recent gains.
Megabux, Ok Mate. Nice Buy come in at 9.45am for £1.122M @ 68p. Nice to see.
Needs a good read. With Finncap Upgrading their Corporate Target from 8.00p to 10.00p. Last week Holdings were increased ( See above ) Looks like one to keep an eye on.
When the SP settles this could be one to look at longer term. Maybe not right now. It's a mega set up in terms of coverage.
I noticed there was a bit of selling when Gable announced it has agreed to issue 125,000 new ordinary shares of 0.25p each following the exercise of employee share options. Application has been made for the 125,000 new ordinary shares to be admitted to trading on AIM and it is expected that admission will take place on 4 April 2014 ("Admission"). The new ordinary shares will represent 0.26% of the enlarged share capital and will rank equally with all other ordinary shares currently in issue___________ Can't be sure if that was coincidence or whether a few investors didn't like the fact. See what tomorrow the 04th brings.
http://www.investegate.co.uk/omg-plc--omg-/rns/holding-s--in-company/201404030847359538D/
Good start in the UK http://investors.dominos.co.uk/media/news/quarter-one-interim-management-statement-3
Blocklisting above. Looks Internal.
Odey Absolute Return Fund has a position of 10.73%. ___Odey European Inc. has a position of 3.74%.
This was almost seven times oversubscribed and a record high for a Cambridge biotech on AIM: It is also in the top five largest IPOs ever by a non-therapeutic UK biotech. The group has a broad international customer base including pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centres around the world. 2013 revenues were derived from 353 unique customers including AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, Merck & Co., Novartis Institute of Biomedical Research and Takeda. Horizon’s proprietary translational genomics platform, GENESIS™ – comprising three gene-editing tools: rAAV (under exclusive licence), ZFN (under non-exclusive licence) and CRISPR (under non-exclusive licence) – offers a precise and flexible gene-editing solution. The group operates a powerful business model, differentiated from typical biotechnology companies, where it can leverage both internally-funded and customer-funded cell line development, drug discovery services and cell line and derivative reagent product offerings. Additional leverage is achieved by combining the offering with novel IP, oncology and drug discovery expertise allowing the Group to accrue downstream milestones and the potential for product royalties. Horizon supplies its services and products into multiple markets, including the translational genomics research market; the cell based assays market; the molecular diagnostics market; and the bioproduction market. Combined, the directors estimate these markets to total more than £29 billion ($48bn) by 2015. Horizon plans to use the cash to broaden its product portfolio and service offering as well for aggressive territorial expansion globally. .